XML 24 R9.htm IDEA: XBRL DOCUMENT

Segment Reporting

12 Months Ended

Jun. 30, 2024

NOTE 4. SEGMENT REPORTING

Identification of reportable operating segments

Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who are identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Cancer Immunotherapy.


Operating segment information June 30, 2024	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		119,089			—		119,089
Grant income		3,722,788			—		3,722,788
Net gain on foreign exchange		—			113,458		113,458
Interest income		—			3,882,757		3,882,757

Total revenue and other income		3,841,877			3,996,215		7,838,092

Result
Segment Result		(46,556,929	)		3,840,304		(42,716,625	)

Profit/(loss) before income tax expense		(46,556,929	)		3,840,304		(42,716,625	)

Income tax expense		—			—		—

Loss after income tax expense							(42,716,625	)
Total segment assets		201,579,281			—		201,579,281
Total segment liabilities		12,057,539			—		12,057,539


Operating segment information June 30, 2023	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		191,721			—		191,721
Grant income		3,314,001			—		3,314,001
Net gain on fair value movement of warrants		—			131,896		131,896
Net gain on foreign exchange		—			623,511		623,511
Interest income		—			938,999		938,999

Total revenue and other income		3,505,722			1,694,406		5,200,128

Result
Segment Result		(41,431,305	)		1,534,957		(39,896,348	)
Profit/(loss) before income tax expense		(41,431,305	)		1,534,957		(39,896,348	)
Income tax expense		—			—		—
Loss after income tax expense							(39,896,348	)

Total segment assets		147,448,990			—		147,448,990
Total segment liabilities		10,979,601			—		10,979,601


Operating segment information June 30, 2022	Immunotherapy A$			Unallocated A$			Consolidated A$
Revenue
License revenue		170,369			—			170,369
Other income
Research material sales		84,018			—			84,018
Grant income		4,459,974			—			4,459,974
Net gain on fair value movement of warrants		—			591,070			591,070
Net gain on foreign exchange		—			1,228,122			1,228,122
Interest income		—			224,520			224,520

Total revenue and other income		4,714,361			2,043,712			6,758,073

Result
Segment Result		(33,929,768	)		(1,718,976	)		(32,210,792	)

Profit/(loss) before income tax expense		(33,929,768	)		(1,718,976	)		(32,210,792	)
Income tax expense								(34	)

Loss after income tax expense								(32,210,826	)

Total segment assets		102,169,550			—			102,169,550
Total segment liabilities		8,092,184			—			8,092,184